Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Assets: 2019-2024

Historic Current Assets for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $257.8 million.

  • C4 Therapeutics' Current Assets fell 24.29% to $206.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.9 million, marking a year-over-year decrease of 24.29%. This contributed to the annual value of $257.8 million for FY2024, which is 4.95% down from last year.
  • C4 Therapeutics' Current Assets amounted to $257.8 million in FY2024, which was down 4.95% from $271.2 million recorded in FY2023.
  • C4 Therapeutics' 5-year Current Assets high stood at $381.0 million for FY2020, and its period low was $257.8 million during FY2024.
  • Moreover, its 3-year median value for Current Assets was $271.2 million (2023), whereas its average is $272.2 million.
  • As far as peak fluctuations go, C4 Therapeutics' Current Assets surged by 293.74% in 2020, and later dropped by 14.52% in 2021.
  • Over the past 5 years, C4 Therapeutics' Current Assets (Yearly) stood at $381.0 million in 2020, then decreased by 14.52% to $325.7 million in 2021, then declined by 11.71% to $287.6 million in 2022, then dropped by 5.69% to $271.2 million in 2023, then dropped by 4.95% to $257.8 million in 2024.